Pharmedium Recalls Esmolol HCl Due to Lack of Sterility Assurance
Pharmedium Services, LLC is recalling Esmolol HCl in all strengths and packaging due to a lack of sterility assurance.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 4/5 (Severe).
The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The agency classified this as an FDA Class II recall. Per the rubric, FDA Class II recalls involving significant risks such as sterility issues in injectable medications are categorized as Severe.
Plain-English summary
Pharmedium Services, LLC is voluntarily recalling Esmolol HCl in all strengths, doses, and packaging. The recall is being conducted because of a lack of sterility assurance in the product.
The affected product is distributed nationwide in the United States. The recall includes all lots of the medication that are remaining within their expiration dates.
Consumers who have this product should stop using it and contact their healthcare provider or pharmacist for further instructions.
The recalled product
- Product
- Esmolol HCl in all strengths, all doses, and all packaging.
- Manufacturer
- Pharmedium Services, LLC
- Category
- Drug — Injectable Medication
- Hazard
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- All lots remaining within expiry.
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 42 recalled by Pharmedium Services, LLC under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 42 products in this recall →Related recalls
Same manufacturer · Pharmedium Services, LLC
See all →- SeverePharMEDium Recalls nICARdipine HCl Injection Due to Sterility Assurance Concerns
FDA (Drugs) · 2020-04-15
- SeverePharMEDium Recalls ePHEDrine Sulfate Syringes Due to Sterility Assurance Issues
FDA (Drugs) · 2020-04-15
- SeverePharMEDium Recalls Fentanyl Citrate Injection Due to Sterility Assurance Concerns
FDA (Drugs) · 2020-04-15
- SeverePharMEDium Recalls Fentanyl Citrate Infusions Due to Sterility Assurance Issues
FDA (Drugs) · 2020-04-15
- SeverePharMEDium Recalls Rocuronium Bromide Syringes Due to Sterility Assurance Issues
FDA (Drugs) · 2020-04-15
Same hazard · lack of sterility
See all →- SevereK.C. Pharmaceuticals Recalls Dry Eye Relief Eye Drops for Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereK.C. Pharmaceuticals Recalls Multiple Brands of Eye Drops for Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereClear Eyes Redness Relief Eye Drops Recalled for Sterility Concerns
FDA (Drugs) · 2026-09-30
- SevereClear Eyes Redness Relief Eye Drops Recalled for Sterility Assurance Issues
FDA (Drugs) · 2026-09-30
- SevereGentle Eyes Lubricant Eye Drops Recalled for Sterility Concerns
FDA (Drugs) · 2026-09-30
Similar recalls
- SeverePharMEDium Recalls Phenylephrine Injection Due to Sterility Assurance Failure
FDA (Drugs) · 2018-02-21
- ModeratePharmedium Recalls Labetalol HCl Syringes Due to Stability Data Concerns
FDA (Drugs) · 2016-10-19
- SeverePhosphatidylcholine Injectable Recalled for Lack of Sterility Assurance
FDA (Drugs) · 2013-05-01
- SeverePharMEDium Recalls Succinylcholine Chloride Vials Due to Sterility Concerns
FDA (Drugs) · 2016-11-09
- SeverePharmakon Recalls Midazolam HCl Bags Due to Sterility Concerns
FDA (Drugs) · 2016-07-20
- SeverePharmedium Recalls Ketamine HCl Injection Due to Potential Loss of Potency
FDA (Drugs) · 2016-10-19